Source comparison
PT-141 Side Effects: Research vs Clinical Trial Comparison
Nausea 40–50% first dose, decreases to 24% by dose 8 30–90 minutes post-admin 2–12 hours, high individual variation Yes. 1.75mg produces 2× incidence vs 1.25mg Most common cause of discontinuation in week 1; tachyphylaxis develops rapidly Facial Flushing 25–35
This comparison does not assign a generated winner or score.
- Nausea
- 40–50% first dose, decreases to 24% by dose 8
- 30–90 minutes post-admin
- 2–12 hours, high individual variation
- Yes. 1.75mg produces 2× incidence vs 1.25mg
- Most common cause of discontinuation in week 1; tachyphylaxis develops rapidly
- Facial Flushing
- 25–35% across all doses
- 30–60 minutes post-admin
- 2–4 hours
- Moderate correlation with dose
- Benign, does not predict cardiovascular risk
- Transient Hypertension
- 10–15 mmHg systolic elevation in normotensive subjects
- 60–90 minutes (peak effect)
- Returns to baseline by 6–8 hours
- Strong dose correlation. 40% dose increase yields 3× BP response
- Requires baseline screening; contraindicated in uncontrolled HTN
- Headache
- 15–25%
- 3–6 hours
- Weak dose correlation
- Tension-type phenotype, responds to standard analgesics
- Injection Site Reaction
- <5% with proper technique
- Immediate
- 30–60 minutes if mild, 24 hours if technique error
- Not dose-dependent. Technique-dependent
- Almost always indicates technical error in reconstitution or injection
- The most striking finding across published trials is that PT-141 side effects rarely necessitate medical intervention. Only 3% of subjects in the RECONNECT trials required treatment for adverse events beyond standard supportive care (oral ondansetron for nausea, acetaminophen for headache). The high discontinuation rate (approximately 15% in phase 3 trials) reflects tolerability rather than safety concerns. Subjects discontinued because the experience was unpleasant, not because they were medically unstable. This distinction matters for research protocol design: incorporating a run-in period where subjects receive a single test dose before committing to the full study allows self-selection of those who tolerate the peptide, reducing costly mid-protocol dropouts.